Table 1.

Clinicopathologic characteristics of CML patients

n
 Gender
Female28
Male38
Mean age at diagnosis54 y (range, 26–83)
Bcr-Abl transcript
p210 b3a250
p210 b2a214
p210 b2a2 and p1902
Stage at the end of the study
CP57
Accelerated phase0
BC9
Response to treatment at the end of the study by cytologic, cytogenetic, and molecular status
Too early to evaluate response3
HR8
mCR7
CCR7
MMR24
CMR17
Response to treatment at the end of the study [as ELN recommendations (51)]
Too early to evaluate response3
Failure9 (8 HR, 1 mCR)
Suboptimal response10 (6 mCR, 1 MCR, 1 CCR, 1 MMR, 1 CMR)
Optimal response40 (6 CCR, 21 MMR, 13 CMR)
No data to evaluate response with these criteria4 (1 CCR, 2 MMR, 1 CMR)
Treatment
Imatinib only31
IFN first line + imatinib22
HU/BU first line + imatinib13

Abbreviation: mCR, minor cytogenetic response.